Stock listing
NASDAQ:NXTC NextCure, Inc. Stock
Home listing (NASDAQ) of NextCure, Inc.
Follow NextCure, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:NXTC
$6.45 USD -0.43 (-6.3%)
Close on Nov 20, 2026
- Day range
- $6.45 – $6.96 USDNov 20, 2026
- Volume
- 30,624 sharesNov 20, 2026
- Market cap
- $29.53M USDAt the close on Nov 20, 2026 · price × 4.58M shares outstanding
- 52-week range
- $1.55 – $15.74 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $485,922 USDMedian day 71,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NXTC · Home | $6.45 USD | -0.435 (-6.3%) | 30,624 | $6.60 | $6.96 | $6.45 | $6.885 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NXTC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.45 | -0.435 | -6.3% | $6.60 | $6.96 | $6.45 | 30,624 | |
| $6.885 | +0.185 | +2.8% | $6.38 | $7.005 | $6.38 | 21,403 | |
| $6.70 | +0.02 | +0.3% | $6.75 | $7.25 | $6.38 | 78,011 | |
| $6.68 | +0.28 | +4.4% | $6.085 | $6.99 | $5.75 | 37,744 | |
| $6.40 | +0.17 | +2.7% | $6.14 | $6.57 | $6.14 | 37,678 | |
| $6.23 | +0.25 | +4.2% | $5.95 | $6.30 | $5.37 | 43,034 | |
| $5.98 | 0.00 | 0.0% | $5.757 | $6.30 | $5.008 | 93,166 | |
| $5.98 | -0.29 | -4.6% | $6.15 | $6.29 | $5.60 | 81,524 | |
| $6.27 | +0.94 | +17.6% | $5.46 | $6.35 | $5.305 | 58,474 | |
| $5.33 | +0.21 | +4.1% | $5.415 | $5.71 | $5.10 | 49,805 | |
| $5.12 | -0.73 | -12.5% | $5.545 | $5.59 | $5.10 | 24,057 | |
| $5.85 | -0.06 | -1.0% | $6.01 | $6.435 | $5.41 | 38,975 | |
| $5.91 | +0.215 | +3.8% | $5.71 | $6.04 | $5.60 | 33,131 | |
| $5.695 | -0.615 | -9.7% | $6.41 | $6.51 | $5.33 | 64,063 | |
| $6.31 | -0.215 | -3.3% | $6.32 | $6.58 | $6.24 | 19,106 | |
| $6.525 | +0.185 | +2.9% | $6.06 | $6.66 | $5.844 | 58,256 | |
| $6.34 | +0.625 | +10.9% | $5.72 | $6.41 | $5.627 | 64,391 | |
| $5.715 | +0.49 | +9.4% | $5.305 | $5.785 | $4.86 | 142,061 | |
| $5.225 | +0.245 | +4.9% | $4.91 | $5.48 | $4.776 | 25,195 | |
| $4.98 | +0.26 | +5.5% | $4.96 | $5.28 | $4.529 | 48,500 | |
| $4.72 | -0.695 | -12.8% | $5.28 | $5.85 | $4.61 | 71,100 | |
| $5.415 | -0.025 | -0.5% | $5.51 | $6.042 | $5.25 | 71,500 | |
| $5.44 | -0.23 | -4.1% | $5.87 | $6.10 | $5.327 | 82,100 | |
| $5.67 | -0.57 | -9.1% | $6.16 | $6.46 | $5.45 | 67,300 | |
| $6.24 | -0.64 | -9.3% | $6.615 | $6.66 | $6.08 | 39,000 | |
| $6.88 | +0.30 | +4.6% | $6.593 | $7.22 | $6.593 | 72,400 | |
| $6.58 | +0.30 | +4.8% | $6.16 | $6.858 | $6.11 | 51,600 | |
| $6.28 | -0.36 | -5.4% | $6.58 | $6.80 | $6.21 | 54,700 | |
| $6.64 | -0.54 | -7.5% | $7.08 | $7.52 | $6.03 | 130,400 | |
| $7.18 | +0.40 | +5.9% | $6.675 | $7.20 | $6.30 | 85,700 | |
| $6.78 | +0.22 | +3.4% | $6.24 | $6.94 | $6.048 | 82,600 | |
| $6.56 | +0.875 | +15.4% | $5.70 | $6.72 | $5.42 | 109,500 | |
| $5.685 | +0.635 | +12.6% | $5.01 | $5.905 | $5.00 | 122,500 | |
| $5.05 | -0.04 | -0.8% | $5.05 | $5.19 | $4.94 | 14,600 | |
| $5.09 | +0.13 | +2.6% | $5.17 | $5.40 | $4.85 | 63,300 | |
| $4.96 | -0.05 | -1.0% | $4.99 | $5.19 | $4.85 | 46,500 | |
| $5.01 | +0.165 | +3.4% | $5.14 | $5.165 | $4.91 | 34,100 | |
| $4.845 | -0.235 | -4.6% | $5.00 | $5.22 | $4.78 | 55,400 | |
| $5.08 | 0.00 | 0.0% | $5.02 | $5.305 | $5.00 | 63,200 | |
| $5.08 | -0.20 | -3.8% | $5.27 | $5.56 | $5.023 | 71,800 | |
| $5.28 | +0.46 | +9.5% | $4.80 | $5.65 | $4.80 | 226,800 | |
| $4.82 | -0.36 | -6.9% | $5.12 | $5.19 | $4.64 | 225,800 | |
| $5.18 | -0.28 | -5.1% | $5.59 | $5.90 | $4.87 | 156,100 | |
| $5.46 | -0.66 | -10.8% | $6.09 | $6.30 | $5.32 | 125,900 | |
| $6.12 | +0.45 | +7.9% | $5.87 | $6.27 | $5.67 | 103,200 | |
| $5.67 | -0.36 | -6.0% | $6.05 | $6.38 | $5.54 | 106,800 | |
| $6.03 | -0.34 | -5.3% | $6.55 | $6.63 | $5.765 | 106,700 | |
| $6.37 | -0.27 | -4.1% | $6.65 | $6.735 | $6.06 | 157,400 | |
| $6.64 | -0.36 | -5.1% | $6.82 | $7.00 | $6.20 | 90,600 | |
| $7.00 | -0.31 | -4.2% | $7.33 | $7.78 | $6.88 | 115,300 | |
| $7.31 | -0.76 | -9.4% | $7.99 | $8.17 | $7.055 | 55,800 | |
| $8.07 | -0.35 | -4.2% | $8.57 | $8.57 | $7.69 | 42,900 | |
| $8.42 | +0.60 | +7.7% | $7.47 | $8.64 | $7.05 | 95,000 | |
| $7.82 | -0.02 | -0.3% | $7.79 | $8.23 | $7.57 | 60,600 | |
| $7.84 | +0.49 | +6.7% | $7.48 | $8.30 | $7.106 | 161,400 | |
| $7.35 | +0.55 | +8.1% | $6.70 | $7.44 | $6.475 | 112,600 | |
| $6.80 | +0.41 | +6.4% | $6.38 | $6.86 | $6.16 | 112,900 | |
| $6.39 | +0.30 | +4.9% | $6.13 | $6.58 | $6.078 | 54,700 | |
| $6.09 | +0.055 | +0.9% | $5.98 | $6.20 | $5.93 | 60,800 | |
| $6.035 | +0.205 | +3.5% | $5.95 | $6.34 | $5.932 | 73,300 | |
| $5.83 | -0.08 | -1.4% | $5.85 | $6.19 | $5.60 | 91,100 | |
| $5.91 | +0.02 | +0.3% | $5.93 | $6.759 | $5.84 | 160,415 | |
| $5.89 | -0.40 | -6.4% | $6.20 | $6.629 | $5.69 | 121,650 | |
| $6.29 | +0.04 | +0.6% | $6.19 | $6.58 | $6.19 | 37,000 | |
| $6.25 | -0.53 | -7.8% | $6.55 | $6.725 | $6.00 | 86,000 |
Splits
1 split · NASDAQ:NXTC · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation |
- Ticker
- NASDAQ:NXTC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
Latest deck · Aug 10, 2026
Merger or Acquisition (August 2026)
Merger or acquisition · 21 slides
Latest news
NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
Nov 10, 2026
Closed $5.98 (0.0%) on Nov 11, 2026
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
Aug 6, 2026
Closed $5.84 (+4.5%) on Aug 7, 2026
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
Jul 14, 2026
Closed $6.58 (+201.8%) on Jul 14, 2026
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
Jun 4, 2026
Closed $3.19 (+1.3%) on Jun 4, 2026
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
Jun 1, 2026
Closed $3.38 (-45.5%) on Jun 1, 2026
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
May 7, 2026
Closed $9.76 (-4.1%) on May 8, 2026
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
May 4, 2026
Closed $8.92 (-4.7%) on May 4, 2026
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
Apr 7, 2026
Closed $11.13 (+0.9%) on Apr 7, 2026
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
Mar 31, 2026
Closed $10.53 (-1.4%) on Apr 1, 2026
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
Mar 5, 2026
Closed $12.76 (+1.3%) on Mar 5, 2026
NextCure, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 11 in the last 12 months · 79 in all · newest Nov 10, 2026 · oldest 2019
- Decks
- 15 decks · latest Aug 10, 2026
Where NextCure, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NXTC · Home listing · This page | NASDAQ | United States | USD |
| BOATS:NXTC | BOATS | United States | USD |
| Frankfurt:2US0 | Frankfurt | Germany | EUR |
| gettex:2US0 | gettex | Germany | EUR |
| Lang & Schwarz:A41AKJ | Lang & Schwarz | Germany | EUR |
| LS Exchange:A41AKJ | LS Exchange | Germany | EUR |
| Munich:2US0 | Munich | Germany | EUR |
Valuation
Price/book 5.4× against a median of 2.0×: 8th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $20.81M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.85
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| NextCure, Inc. · NASDAQ:NXTC | US$29.53M | US$20.81M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.85 |
| Kalaris Therapeutics, Inc. · NASDAQ:KLRS | US$30.47M | −US$51.05M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.47 |
| Pacific Software, Inc. · OTC:PFSF | US$29.86M | US$38.10M | n/a | n/a | n/a | n/a | n/a | n/a | 1.57 |
| NurExone Biologic Inc · TSXV:NRX | US$29.53M | US$28.52M | n/a | n/a | n/a | 23.3× | n/a | 0.0× | 0.00 |
| BioHarvest Sciences, Inc. · NASDAQ:BHST | US$29.47M | US$34.54M | n/a | 1.0× | n/a | 1.8× | −34.7% | 1.0× | 0.43 |
| Thiogenesis Therapeutics Corp · TSXV:TTI | US$29.28M | US$24.21M | n/a | n/a | n/a | 6.2× | n/a | 0.0× | 0.37 |
| NanoViricides, Inc. · AMEX:NNVC | US$29.11M | US$26.54M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | 1.82 |
| Rein Therapeutics, Inc. · NASDAQ:RNTX | US$29.06M | −US$6.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 2.11 |
| Nicox SA · EURONEXT:ALCOX | US$29.05M | US$25.67M | n/a | 1.4× | n/a | 3.8× | −14.4% | 0.4× | n/a |
| Serina Therapeutics, Inc. · AMEX:SER | US$28.45M | US$12.42M | n/a | 99.3× | n/a | 2.0× | n/a | 0.2× | 1.60 |
| ProMIS Neurosciences Inc. · NASDAQ:PMN | US$28.43M | −US$15.68M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.83 |
| Median of the others | US$29.20M | US$24.94M | 1.4× | 2.0× | −24.5% | 0.0× | 0.83 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 20.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.34 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Michael Richman | President & CEO |
| Steven P. Cobourn | CFO |
| Timothy Mayer | COO |
| Kevin Shaw | General Counsel |
| Dallas Flies | Vice President, Discovery Research |
| Sebastien Maloveste | Senior Vice President, Business Development |
| Sourav Kundu | Senior Vice President, Development & Manufacturing |
Board
| Director | Role |
|---|---|
| David Kabakoff | Chairman |
| Anne Borgman | Director |
| Elaine V. Jones | Director |
| Ellen G. Feigal | Director |
| John G. Houston | Director |
| Michael Richman | President & CEO |
| Stephen Webster | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · After close | 0.0% |
| Q2 2026 | Aug 6, 2026 · After close | +4.5% |
| Q1 2026 | May 7, 2026 · After close | −4.1% |
| Q4 2025 | Mar 6, 2026 | −2.0% |
| Q3 2025 | Nov 5, 2025 · After close | +2.0% |
| Q2 2025 | Aug 7, 2025 · After close | −4.4% |
| Q1 2025 | May 1, 2025 · After close | −7.7% |
| Q4 2024 | Mar 19, 2025 · Before open | +0.2% |
| Q3 2024 | Nov 7, 2024 · After close | −2.3% |
| Q2 2024 | Aug 1, 2024 · After close | −0.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · After close | +2.7% |
| Q4 2023 | Mar 21, 2024 · Before open | +19.1% |
| Q3 2023 | Nov 2, 2023 · After close | +0.8% |
| Q2 2023 | Aug 3, 2023 · After close | −1.2% |
| Q1 2023 | May 4, 2023 · After close | 0.0% |
| Q4 2022 | Mar 2, 2023 · After close | −4.5% |
| Q3 2022 | Nov 3, 2022 · After close | −21.1% |
| Q2 2022 | Aug 4, 2022 · After close | +6.3% |
| Q1 2022 | May 5, 2022 · After close | −2.1% |
| Q4 2021 | Mar 3, 2022 · After close | −0.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (August 2026) | Merger or acquisition | 21 slides | Aug 10, 2026 |
| Merger or Acquisition (August 2026) | Merger or acquisition | 20 slides | Aug 4, 2026 |
| Investor Presentation (August 2026) | Investor deck | 16 slides | August 2026 |
| Avere Therapeutics — Merger or Acquisition (July 2026) | Merger or acquisition | 20 slides | July 2026 |
| Technical Presentation (June 2026) | Technical | 26 slides | Jun 2, 2026 |
| Investor Presentation (June 2026) | Investor deck | 31 slides | Jun 1, 2026 |
| Investor Presentation (January 2026) | Investor deck | 28 slides | Jan 23, 2026 |
| Investor Presentation (June 2025) | Investor deck | 25 slides | Jun 16, 2025 |
| Investor Presentation (April 2025) | Investor deck | 16 slides | Apr 10, 2025 |
| Investor Presentation (December 2024) | Investor deck | 20 slides | Dec 5, 2024 |
All 15 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2024) | Investor deck | 20 slides | Nov 8, 2024 |
| Investor Presentation (March 2024) | Investor deck | 38 slides | Mar 21, 2024 |
| Investor Presentation (March 2022) | Investor deck | 27 slides | Mar 3, 2022 |
| Corporate Update (November 2021) | Corporate update | 45 slides | Nov 15, 2021 |
| Technical Presentation | Technical | 15 slides |
Financings
| Raise | Date |
|---|---|
| Private placement of private placement concurrent with the Merger Made bigger: about US$820M Use of proceeds: To advance development of AVR-001 and support future operations of the combined company after the Merger. | Nov 10, 2026 |
| Private placement of shares of common stock and pre-funded warrants Closed: US$21.5M raised · US$8.52 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Buyers: Ikarian Capital; Squadron Capital Management; Affinity Healthcare Fund, LP.; Exome Asset Management; Affinity Healthcare Fund, LP Use of proceeds: General working capital, extending cash runway into first half of 2027, beyond first half 2026 proof of concept data readouts of SIM0505 and LNCB74 | Nov 17, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$15.00 a share on May 8, 2019.
- Price
- US$15.00 a share
- Shares offered
- 5,000,000 shares of common stock
- Offering size
- US$75 million
- Underwriters' option
- Up to 750,000 more shares
- Listing
- NXTC on the Nasdaq Global Select Market
- Underwriters
- MORGAN STANLEY, BofA MERRILL LYNCH, PIPER JAFFRAY · In the order on the cover
- Shares delivered
- On or about May 13, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jan 30, 2019 |
| Filed publicly | Apr 12, 2019 |
| Amended 3 times | Newest May 8, 2019 |
| Shares registered with an exchange | May 8, 2019 |
| Declared effective by the SEC | May 8, 2019 |
| Final prospectus, with the price | May 9, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 9, 2019 |
| EFFECT · Notice that a registration is effective | May 8, 2019 |
| S-1/A · Registration statement, amended | May 8, 2019 |
| CERT · Exchange's certificate of listing | May 8, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | May 8, 2019 |
| CORRESP · Letter to the SEC | May 6, 2019 |
| S-1/A · Registration statement, amended | May 3, 2019 |
| S-1/A · Registration statement, amended | Apr 29, 2019 |
| CORRESP · Letter to the SEC | Apr 17, 2019 |
| S-1 · Registration statement | Apr 12, 2019 |
All 18 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | Apr 1, 2019 |
| DRS/A · Draft registration statement, amended | Apr 1, 2019 |
| UPLOAD · Letter from the SEC | Mar 13, 2019 |
| DRSLTR · Letter to the SEC with a draft | Mar 5, 2019 |
| DRS/A · Draft registration statement, amended | Mar 5, 2019 |
| UPLOAD · Letter from the SEC | Feb 25, 2019 |
| DRSLTR · Letter to the SEC with a draft | Jan 30, 2019 |
| DRS · Draft registration statement | Jan 30, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed May 9, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 22.4M | 6.35M | 0 | 0 |
| Cost of revenue | 2.19M | 2.87M | 3.68M | 4.48M | 4.30M | 46.6K | 34.2M | 1.68M | 582.0K |
| Gross profit | -2.19M | -2.87M | -3.68M | -4.48M | -4.30M | 22.4M | -27.9M | -1.68M | -582.0K |
| Research and development | 44.9M | 41.5M | 47.9M | 54.2M | 50.2M | 46.6M | 34.2M | 19.8M | 13.0M |
| Selling, general and administrative | 12.7M | 15.7M | 19.7M | 21.7M | 20.6M | 17.0M | 9.61M | 3.41M | 2.60M |
| Operating income | -57.6M | -59.7M | -67.6M | -75.9M | -70.8M | -41.2M | -37.5M | -23.2M | -15.5M |
| Depreciation and amortization | 2.20M | 2.90M | 3.70M | 4.10M | 4.30M | 3.40M | 2.69M | 1.68M | 582.0K |
| EBITDA | -55.4M | -56.8M | -63.9M | -71.8M | -66.5M | -37.8M | -34.8M | -21.5M | -15.0M |
| Interest expense | 5.30M | 77.0K | 183.0K | 209.0K | 25.0K | 0 | |||
| Income before tax | -55.8M | -55.7M | -62.7M | -74.7M | -69.4M | -36.6M | -33.7M | -22.8M | -15.5M |
| Income tax | 0 | -5.30M | 6.96M | -3.41M | 2.52M | 397.0K | 0 | ||
| Net income | -55.8M | -55.7M | -62.7M | -74.7M | -69.4M | -36.6M | -33.7M | -22.8M | -15.5M |
| Earnings per share, basic | -19.65 | -23.88 | -2.25 | -2.69 | -2.51 | -1.33 | -2.15 | -16.64 | -8.17 |
| Earnings per share, diluted | -19.65 | -23.88 | -2.25 | -2.69 | -2.51 | -1.33 | -2.15 | -16.64 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 26.0M | 27.7M | 13.1M | 26.6M | 12.3M | 32.8M | 34.1M | 135.2M | 8.43M |
| Short-term investments | 15.8M | 40.9M | 95.2M | 133.3M | 207.3M | 250.7M | 300.5M | 0 | 0 |
| Receivables | 100.0K | 300.0K | 800.0K | 700.0K | |||||
| Inventory | -700.0K | 0 | 0 | ||||||
| Current assets | 43.7M | 71.8M | 112.7M | 164.0M | 227.8M | 288.0M | 340.0M | 135.8M | 9.42M |
| Property, plant and equipment | 3.27M | 5.46M | 9.03M | 11.9M | 14.0M | 15.8M | 12.1M | 11.4M | 10.0M |
| Goodwill | 0 | 0 | |||||||
| Total assets | 50.2M | 80.9M | 128.0M | 184.2M | 242.4M | 306.6M | 356.2M | 147.6M | 19.5M |
| Accounts payable | 2.01M | 5.35M | 2.33M | 4.27M | 1.94M | 3.90M | 1.86M | 2.48M | 1.14M |
| Current liabilities | 10.6M | 9.57M | 6.88M | 9.13M | 6.61M | 10.3M | 15.0M | 10.3M | 3.12M |
| Long-term debt | 1.81M | 3.33M | 73.0K | 460.0K | |||||
| Total debt | 5.15M | 5.95M | 6.61M | 0 | 0 | 3.47M | 5.00M | 460.0K | 964.0K |
| Total liabilities | 15.2M | 15.4M | 13.6M | 16.6M | 9.00M | 12.9M | 34.7M | 32.3M | 43.9M |
| Shareholders' equity | 34.9M | 65.5M | 114.4M | 167.5M | 233.4M | 293.7M | 321.5M | -46.9M | -24.4M |
| Shares outstanding | 3.51M | 2.33M | 27.9M | 27.8M | 27.7M | 27.6M | 27.5M | 1.37M | 1.89M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -49.6M | -40.8M | -53.0M | -53.9M | -57.3M | -45.0M | -35.6M | 7.99M | -12.5M |
| Capital spending | 0 | -474.0K | -820.0K | -2.12M | -2.36M | -7.13M | -3.37M | -3.06M | -8.65M |
| Free cash flow | -49.6M | -41.3M | -53.8M | -56.0M | -59.6M | -52.1M | -39.0M | 4.93M | -21.2M |
| Cash from investing | 25.6M | 55.3M | 39.3M | 68.0M | 36.6M | 43.5M | -303.9M | -3.06M | -8.65M |
| Cash from financing | 22.3M | 144.0K | 154.0K | 200.0K | -3.27M | -1.42M | 243.0M | 121.4M | 24.9M |
| Dividends paid | 0 | 0 | |||||||
| Share buybacks | 200.0K | 208.0K | 112.0K | 238.5M | 122.2M | 25.0M | |||
| Change in cash | -1.75M | 14.6M | -13.5M | 14.3M | -23.9M | -2.85M | -96.5M | 126.3M | 3.69M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 425 | Nov 20, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| 425 | Nov 20, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 9, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EFFECT · Notice that a registration is effective | Nov 9, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Nov 6, 2026 | Offer document | SEC |
| S-4/A · Registration statement, amended | Nov 5, 2026 | Offer document | SEC |
| S-4/A · Registration statement, amended | Oct 30, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 30, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 20, 2026 | Big-stake notice | SEC |
| S-4/A · Registration statement, amended | Sep 30, 2026 | Offer document | SEC |
| 425 | Sep 25, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 25, 2026 | Current report | SEC |
| 8-K · Current report | Sep 3, 2026 | Material contract | SEC |
| S-4 · Registration statement | Aug 18, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 425 | Aug 10, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 425 | Aug 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 29, 2026 | Insider trade | SEC |
| 425 | Jul 16, 2026 | Other filings | SEC |
| 425 | Jul 14, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 14, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 25, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 23, 2026 | Results | SEC |
| 8-K · Current report | Dec 19, 2025 | Current report | SEC |
| 424B5 · Prospectus | Dec 19, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 12, 2025 | Other filings | SEC |
| 424B1 · Prospectus | Dec 11, 2025 | Offer document | SEC |
| D | Dec 9, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 9, 2025 | Other filings | SEC |
| S-3 · Registration statement | Nov 26, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 17, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 24, 2025 | Big-stake notice | SEC |
| 3/A · Initial statement of ownership, amended | Sep 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 25, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 19, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Aug 19, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| EFFECT · Notice that a registration is effective | Jul 30, 2025 | Other filings | SEC |
| 424B2 · Prospectus | Jul 29, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 28, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 24, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jul 18, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 14, 2025 | Current report | SEC |
| 8-K · Current report | Jul 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 16, 2025 | Material contract | SEC |
| DEFA14A · Additional proxy material | May 19, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | May 19, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 15, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 10, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 6, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 3, 2025 | Current report | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| 8-K · Current report | Dec 5, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 8, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 1, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Jun 27, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 21, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 18, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 2, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 2, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Apr 1, 2024 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2024 | Results | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 8, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 19, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 14, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 2, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2023 | Results | SEC |
| EFFECT · Notice that a registration is effective | Aug 14, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 9, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 8, 2023 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 4, 2023 | Offer document | SEC |
| S-3 · Registration statement | Aug 4, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 3, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2023 | Results | SEC |
| 8-K · Current report | Jul 19, 2023 | Management or board change | SEC |
| 8-K · Current report | Jun 26, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 4, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2023 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 424B5 · Prospectus | Apr 3, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 2, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 2, 2023 | Results | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 28, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2023 | Big-stake notice | SEC |
This page holds 200 of 407 filings. Open Filings
Cap table
Built by 6ix from NextCure, Inc.’s releases · as of Nov 9, 2026
- Common shares
- 4,579,023
- Fully diluted
- 4,579,023
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 4,579,023 | Nov 9, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 9, 2026 | 4,579,023 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Briggs Morrison Other companies: CRISPR Therapeutics AG (Director · Since at least Jun 5, 2025); Werewolf Therapeutics, Inc. (Director · Since at least Apr 29, 2021); Arvinas, Inc. (Chair of the Arvinas Board of Directors · Since at least Sep 26, 2018); Carisma Therapeutics, Inc. (Director · Mar 7, 2023 – Jun 26, 2024 · Past); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 17, 2021 · Past); Oncorus Inc (Director · Oct 1, 2020 – Oct 1, 2020 · Past); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past); Syndax Pharmaceuticals, Inc. (Director · Mar 2, 2016 – Feb 7, 2024 · Past) | Director · May 8, 2019 – Jun 11, 2020 · Past |
| Stephen Webster Other companies: Cullinan Therapeutics, Inc. (Chair of the Audit Committee · Since at least Jan 7, 2021); Gritstone bio, Inc. (Director · Apr 26, 2024 – Apr 4, 2025 · Past); Tcr2 Therapeutics Inc (Director · Apr 30, 2020 – Jun 1, 2023 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Aug 2, 2022 · Past); Viking Therapeutics, Inc. (Director · Apr 28, 2015 – Jan 2, 2020 · Past); Spark Therapeutics Inc (CHIEF FINANCIAL OFFICER · Jan 29, 2015 – Dec 17, 2019 · Past); Optimer Pharmaceuticals Inc (Chief Financial Officer · Jun 25, 2012 – Oct 24, 2013 · Past); Adolor Corp (SVP, Finance & CFO · Sep 9, 2010 – Dec 12, 2011 · Past) | Director · Since at least May 8, 2019 |
| Chau Quang Khuong Other companies: Damora Therapeutics, Inc. (Director · Oct 28, 2020 – Jun 14, 2023 · Past); Fusion Pharmaceuticals Inc (Director · Jun 25, 2020 – Jun 14, 2023 · Past); Whitehawk Therapeutics, Inc. (Director · Jun 18, 2019 – Jun 18, 2019 · Past); Synlogic Inc (Director · Jun 5, 2019 – Apr 20, 2021 · Past); Inspire Medical Systems, Inc. (Director · Apr 10, 2019 – Oct 9, 2020 · Past) | Director · May 8, 2019 – Jun 22, 2023 · Past |
| Garry A Nicholson Other companies: TScan Therapeutics, Inc. (Director · Since at least Jun 12, 2024); Day One Biopharmaceuticals Inc (Director · Since at least Sep 12, 2022); G1 Therapeutics Inc (Director · Jun 17, 2021 – Sep 18, 2024 · Past); Turning Point Therapeutics Inc (Director · Jun 2, 2021 – Aug 17, 2022 · Past); Five Prime Therapeutics Inc (Director · Apr 16, 2021 – Apr 16, 2021 · Past) | Director · Jun 24, 2021 – Jun 22, 2023 · Past |
| Elaine V. Jones Other companies: CytomX Therapeutics, Inc. (Director · Since at least May 1, 2019); Ibere Pharmaceuticals (Director · Feb 25, 2021 – Feb 25, 2021 · Past); Gritstone bio, Inc. (Director · Sep 12, 2019 – Apr 4, 2025 · Past); Mersana Therapeutics Inc (Director · Jun 27, 2017 – Jun 27, 2017 · Past) | Director · Since at least May 8, 2019 |
| Michael Richman Other companies: GenVec Inc (Director · Nov 13, 2015 – Jun 16, 2017 · Past); Palvella Therapeutics, Inc. (Director · Jul 15, 2015 – Jun 21, 2023 · Past); Acer Therapeutics Inc (Director · Jun 30, 2015 – Sep 30, 2016 · Past) | President & CEO · Since at least May 8, 2019 |
| Anne Borgman Other companies: Curis, Inc. (Director · Since at least Oct 12, 2022); Sutro Biopharma, Inc. (CHIEF MEDICAL OFFICER · Feb 28, 2023 – May 1, 2025 · Past) | Director · Since at least Jun 23, 2022 |
| John G. Houston Other companies: Arvinas, Inc. (Director · Since at least Jul 11, 2019) | Director · Since at least Sep 10, 2020 |
| Dallas Flies | Vice President, Discovery Research · Since at least Nov 5, 2026 |
| David Kabakoff | Director · Since at least Jun 20, 2024 |
All 19 people
| Person | Seat |
|---|---|
| Ellen G. Feigal | Director · Since at least Nov 5, 2026 |
| Han Myint | Chief Medical Officer · Jan 11, 2021 – Mar 29, 2024 · Past |
| Kevin Shaw | Sr VP, General Counsel · Since at least Jan 31, 2024 |
| Sebastien Maloveste | Senior Vice President, Business Development · Since at least Nov 5, 2026 |
| Sourav Kundu | Sr VP, Dev. & Mfg. · Since at least Jan 31, 2024 |
| Steven P Cobourn | Chief Financial Officer · Since at least Jan 30, 2026 |
| Steven P. Cobourn | CFO · Since at least Nov 4, 2026 |
| Timothy Mayer | COO · Since at least Jan 30, 2026 |
| Udayan Guha | Chief Medical Officer · Since at least Feb 1, 2025 |
Log in to ask 6ix AI your own questions about NextCure, Inc.